OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance. The post Stock Upgrades: Orasure Technologies Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Orasure Technologies Shows Rising Relative Strength

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q3 2020 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of 114.29% and 11.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Beats Q3 Earnings and Revenue Estimates

Net T hird Q uarter R evenues of $ 48.0 M illion Increased 33 % Year-Over-Year, D riven by $ 18 . 4 M illion in S ales of O ral F luid C ollection D evices for COVID-19 M olecular T esting

OraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19 Developments

Second FDA EUA for the Subsidiary's Saliva Collection Devices Second FDA EUA for the Subsidiary's Saliva Collection Devices

OraSure's DNA Genotek Subsidiary Receives FDA Emergency Use Authorization for its ORAcollect®·RNA Saliva Collection Device for SARS CoV-2

OraSure receives emergency use authorization for OMNIgene. Keros Therapeutics initiates Phase 2 clinical trial for Myelodysplastic Syndromes.

OraSure's Emergency Use Authorization, And Other News: The Good, Bad And Ugly Of Biopharma

BETHLEHEM, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, November 4, 2020. 

OraSure Technologies to Hold 2020 Third Quarter Earnings Conference Call  Wednesday, November 4, 2020, 5:00 p.m. ET

The FDA granted Emergency Use Authorization for the company's at-home saliva collection device for coronavirus testing.

Why OraSure Technologies Stock Is Soaring Today

OraSure Technologies (OSUR) is in the news Monday after announcing approval from the FDA for one of its devices sent OSUR stock soaring. The post OraSure Technologies News: Why OSUR Stock Is Surging 13% Today appeared first on InvestorPlace.

OraSure Technologies News: Why OSUR Stock Is Surging 13% Today

Shares of OraSure Technologies, Inc. (NASDAQ: OSUR) were advancing strongly Monday after the diagnostic company said its DNA Genotek subsidiary's saliva collection device used in COVID-19 testing has been approved for emergency use. What Happened: Bethlehem, Pennsylvania-based OraSure said DNA Genotek's OMNIgene ORAL — a saliva collection and stabilization device — has been accorded emergency use authorization.

Why OraSure Shares Are Trading Higher Today

OraSure Technologies Inc. (NASDAQ: OSUR) shares jumped to start off the week after the company announced an update from the U.S.

A Look at the FDA's Most Recent COVID-19 Approval

BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the use of DNA Genotek's OMNIgene®·ORAL (OM-505, OME-505) saliva collection and stabilization device in COVID-19 testing. This is the first FDA EUA that allows for the unsupervised use of the device at-home or in a healthcare setting when used as part of an approved or validated at-home test kit, meaning patients can safely collect their own sample, without the presence of a healthcare professional.

OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

Investors need to pay close attention to OraSure (OSUR) stock based on the movements in the options market lately.

Implied Volatility Surging for OraSure (OSUR) Stock Options

BETHLEHEM, Pa., Sept.  24, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) saliva collection device has been included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Quadrant Biosciences Inc. for a COVID-19 laboratory test. Under the EUA, the ORAcollect®·RNA (OR-100) device can be used to collect saliva samples from individuals suspected of COVID-19 infection by a healthcare professional. This is the sixth EUA to include a collection device from the Company’s DNA Genotek subsidiary and the first to exclusively utilize a saliva collection method.

OraSure’s ORAcollect®·RNA Device Included in EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test

A prominent Harvard epidemiologist and expert in disease testing thinks a cheap, daily, do-it-yourself test can be as effective as a vaccine at cutting coronavirus transmission, according to an article in the Harvard Gazette.

OraSure Hopes to Have 2 Covid-19 Tests Approved by Year-End

BETHLEHEM, Pa., Sept.  03, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) collection device was included along with other devices in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to MiraDx Inc., a Los Angeles-based molecular genetics company. This is the fifth EUA to include a collection device from the company’s DNA Genotek subsidiary.

OraSure’s ORAcollect®·RNA Device Included in EUA Granted to MiraDx Inc. for SARS-CoV-2 Test

A Relative Strength Rating upgrade for Orasure Technologies shows improving technical performance.
The post Stocks With Rising Relative Price Strength: Orasure Technologies appeared first on Investor's Business Daily.

Stocks With Rising Relative Price Strength: Orasure Technologies

OraSure Technologies, Inc. (OSUR) CEO Steve Tang on Q2 2020 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of -77.78% and -14.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Reports Q2 Loss, Lags Revenue Estimates

BETHLEHEM, Pa., Aug.  05, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three and six months ended June 30, 2020.

OraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs

BETHLEHEM, Pa., July  31, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM-505) saliva collection device is included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the United States, for SARS-CoV-2 testing. This is the fourth EUA to include a collection device manufactured and sold by the Company’s DNA Genotek subsidiary.

OraSure’s OMNIgene®·ORAL Device Included in EUA Granted to Clinical Reference Laboratory for  Self-Collected SARS-CoV-2 Saliva Test

OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: OraSure Technologies (OSUR) Q2 Earnings Expected to Decline

2020 Second Quarter Earnings Conference Call   Wednesday, August 5, 2020, 5:00 p.m. ET

OraSure Technologies to Hold Second Quarter 2020 Earnings Conference Call on August 5th, 2020

OTTAWA, June  17, 2020  (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics. A product of OraSure’s DNA Genotek subsidiary, the OMNImet™·GUT (ME-200) augments the Company’s portfolio of multiomic sample collection products.  The device is intended for research use only.

OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics

MORRISVILLE, N.C., June 17, 2020 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temperature storage...

News for OraSure Technologies Stock (OSUR)